TEVA-PHARMACEUTICAL
8.4.2021 09:02:08 CEST | Business Wire | Press release
Teva Pharmaceuticals Europe announced that it has received EU Marketing Authorisation for Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100 and 12.75/202 micrograms delivered doses) as a maintenance treatment for asthma in adults and adolescents aged 12 years and older. Initial launches are planned in Portugal, Switzerland, Spain and the UK.
Introducing Seffalair Spiromax and BroPair Spiromax
The launch of Seffalair Spiromax and BroPair Spiromax further extends Teva’s respiratory portfolio, and provides healthcare professionals another option in treating people living with asthma. Since the launch of DuoResp® Spiromax® (budesonide/formoterol), the Spiromax® inhaler has been well received by healthcare professionals and patients.1,2
Inhaler technique and treatment adherence are key factors in improving outcomes for asthma patients, of which there are an estimated 28 million in the EU.3,4
"We are excited about the European approval of Seffalair Spiromax and BroPair Spiromax, as an important goal of our respiratory franchise is to bring new treatment options to healthcare professionals who support people living with long-term conditions such as asthma,” says Paul Blonk, Head of Teva Respiratory Europe. “We want to empower patients to effectively manage their condition through the medicines we provide, whilst also offering cost-effective treatments to healthcare systems.”
About Seffalair Spiromax and BroPair Spiromax (salmeterol xinafoate / fluticasone propionate)
Seffalair Spiromax and BroPair Spiromax are indicated as a regular treatment for asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β2 agonists.
About Teva Respiratory
Teva Respiratory develops and delivers high-quality treatment options for respiratory conditions, including asthma, COPD and cystic fibrosis. The Teva Respiratory portfolio is centred on optimizing respiratory treatment for patients and healthcare providers through the development of novel delivery systems and therapies that help address unmet needs. Teva’s respiratory pipeline and clinical trial program are based on drug molecules delivered in proprietary dry powder formulations and breath-actuated device technologies, as well as a targeted biologic treatment for severe asthma. Through research and clinical development, Teva Respiratory continually works to expand, strengthen and build upon its treatment portfolio to positively impact the lives of the millions of patients living with respiratory disease.
About Teva
Teva Pharmaceuticals Europe makes life-saving and life-improving medicines more accessible for millions of people around the world. We focus on treatments for migraine, conditions of the central nervous system including pain, as well as respiratory conditions like asthma and COPD and have a portfolio in oncology. Our mission is to be a global leader in generics and biopharmaceuticals improving the lives of patients around the globe.
Building on more than a century-old legacy we have an established presence in generics, specialty, over-the-counter (OTC) and active pharmaceutical ingredients (API). With a fully integrated R&D function, strong operational base and global infrastructure and scale we invest millions of dollars to help our scientists find the next breakthrough.
We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 40,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com .
References
- van der Palen et al. Poster presented at the ERS International Congress, Paris, France, September 2018 (PA1020).
- Roche N, et al. J Asthma, 2021; DOI: 10.1080/02770903.2021.1875482
- GBD. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018. 392 (10159):1789-858.
- Eurostat. First population estimates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005322/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom